TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04952363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A vertical vibration platform PowerVibe Zen Pro 5900
Description: Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFCWO
Description: Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFCWO
Description: Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
Study: NCT03664206

Intervention type: DIAGNOSTIC_TEST
Intervention: MRS, conventional TMS and treshold tracking TMS
Description: Using~* two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~* SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination

Intervention type: DIAGNOSTIC_TEST
Intervention: MRS, conventional TMS and treshold tracking TMS
Description: Using~* two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~* SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination
Study: NCT03462043

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ND0612
Description: s.c. infused

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ND0612
Description: s.c. infused

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ND0612
Description: s.c. infused

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ND0612
Description: s.c. infused

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CLES
Description: Carbidopa-Levodopa Enteral Suspension.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CLES
Description: Carbidopa-Levodopa Enteral Suspension.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CLES
Description: Carbidopa-Levodopa Enteral Suspension.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CLES
Description: Carbidopa-Levodopa Enteral Suspension.
Study: NCT02838784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artacent Human Amniotic Membrane
Description: Double layer dehydrated amnion product

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
Study: NCT02484664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
Study: NCT02350088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: probiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02435056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IEPR Approach
Description: Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~* Minimum Data Set for supporting the diagnosis~* Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~* Second opinion system for improving the management
Study: NCT02560623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Sponge Cell Sampling Device
Description: Undergo swallowable sponge cell sampling assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Sponge Cell Sampling Device
Description: Undergo swallowable sponge cell sampling assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Sponge Cell Sampling Device
Description: Undergo swallowable sponge cell sampling assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Sponge Cell Sampling Device
Description: Undergo swallowable sponge cell sampling assessment
Study: NCT02978612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
Study: NCT00946127

Intervention type: PROCEDURE
Intervention: Ventriculoperitoneal Shunt Placement
Description: In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.

Intervention type: PROCEDURE
Intervention: Endoscopic Third Ventriculostomy(ETV)
Description: Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
Study: NCT03957902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
Study: NCT00099177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bondronat]
Description: 6mg iv on days 1-3, and 50mg po from day 22 to week 24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 4mg iv on day 1, and every 3-4 weeks
Study: NCT00038870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Activated Lymphocyte
Study: NCT04787614

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02452255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate by mouth given daily throughout hospitalization for up to 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate by mouth given daily throughout hospitalization for up to 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth given daily throughout hospitalization for up to 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol by mouth given daily throughout hospitalization for up to 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol by mouth given daily throughout hospitalization for up to 12 months
Study: NCT03457844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT02182830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low dose
Description: starting dose 10mg; forced titration after 4 weeks 25mg dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starting dose 10mg; forced titration after 4 weeks 25mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high dose
Description: starting dose 10mg; forced titration after 4 weeks 25mg dose
Study: NCT04959292

Intervention type: DIAGNOSTIC_TEST
Intervention: arthroscopy
Description: arthroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: arthroscopy
Description: arthroscopy
Study: NCT01924104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: 2500 mIU/day, subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Description: 75 mg/day, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin & aspirin
Description: Aspirin (70 mg/day, orally) \& heparin (40 mg/day, subcutaneously)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Equivalent volume of NaCl 0.9%, subcutaneously
Study: NCT02007655

Intervention type: DRUG
Intervention: Eliquis
Study: NCT00815477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle counseling messages
Description: 10 email messages based on readiness-to-change over a 4 month period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Information
Description: Waitlist control plus educational material on lifestyle behavior and hyptertension
Study: NCT01441856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or Laparoscopic left hemihepatectomy
Description: Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or Laparoscopic left hemihepatectomy
Description: Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or Laparoscopic right hemihepatectomy
Description: Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or Laparoscopic right hemihepatectomy
Description: Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
Study: NCT00662428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom based discharge management
Description: Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
Study: NCT04404829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: The first level of IMT was treated in this study: the objective is to harmonize the cranio-sacral and sacro-pelvic systems, as this is fundamental for maintaining good posture. The first therapeutic maneuvers should be focused on releasing of the sacrum and the pelvis. The first is considered a key area for the correct transmission of forces and loads from the lower limbs to the upper limbs and vice versa and shares the role of rigid elements for this purpose (bones) and tensile elements (muscles, ligaments, fascia) in the whole body. In this level. Compensatory injuries that the body has started after a primary injury are treated on this level, through the Fluidic Chains. The diagnosis of this level is performed by cranial somotopias. Practically all the treatment is carried out on the sacrum. The first step are the fuses, which are vibration zones which act as a protection system for the body. These points sometimes stop working, which interrupts the correct movement of the PRM.
Study: NCT00631163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Description: The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
Study: NCT01300156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy (ESHAOx)
Description: * Etoposide 40 mg/m2, D1-4~* Methylprednisolone 500mg, D1-5~* Cytarabine 2 g/m2, D5~* Oxaliplatin 130 mg/m2, D1
Study: NCT01080859

Intervention type: DEVICE
Intervention: OCT
Description: Optical coherence tomography

Intervention type: DEVICE
Intervention: OCT
Description: Optical coherence tomography
Study: NCT02208050

Intervention type: DRUG
Group type: OTHER
Intervention: Fampridine

Intervention type: DRUG
Group type: OTHER
Intervention: Fampridine

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT00421109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Encapsulated 20 mg Tablet. Once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: Encapsulated 5 mg tablet. Once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablet. Once daily for 28 days
Study: NCT02945111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time view

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No visual support
Study: NCT00579332

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: brassica intervention
Description: diet and phyto-chemical intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: brassica intervention
Description: diet and phyto-chemical intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: brassica intervention
Description: diet and phyto-chemical intervention
Study: NCT02290379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-201 35 mg
Description: Drug: TNX-201 35 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-201 70 mg
Description: Drug: TNX-201 70 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-201 140 mg
Description: Drug: TNX-201 140 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic isometheptene 70 mg
Description: Active Comparator: Racemic isometheptene 70 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo
Study: NCT03372642

Intervention type: DEVICE
Intervention: Subtalar endorthesis
Description: Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
Study: NCT01685385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients who will receive the BNP test
Description: Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
Study: NCT03871829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib 20 mg/m^2
Description: Carfilzomib 20 mg/m\^2 will be administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib 20 mg/m^2
Description: Carfilzomib 20 mg/m\^2 will be administered intravenously (IV).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib 70 mg/m^2
Description: Carfilzomib 70 mg/m\^2 will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib 70 mg/m^2
Description: Carfilzomib 70 mg/m\^2 will be administered IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 40 mg
Description: Dexamethasone 40 mg will be administered as IV infusion or orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 40 mg
Description: Dexamethasone 40 mg will be administered as IV infusion or orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara-SC 1800 mg
Description: Dara-SC 1800 mg will be administered by SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 20 mg
Description: Dexamethasone 20 mg will be administered as IV infusion or orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg
Description: Dexamethasone 20 mg will be administered as IV infusion or orally.
Study: NCT00528073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin-EIR
Description: Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin-EIR
Description: Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin-EIR
Description: Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin-EIR
Description: Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
Study: NCT03705845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo softgel
Description: Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DeltaGold® Tocotrienol 70%
Description: DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
Study: NCT02546596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-hyperthermia
Description: Addition of electro-hyperthermia to radiation
Study: NCT05376072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyographic Biofeedback
Description: The players performed 10 work sessions with EMG-BF. Each session was divided into three phases: (a) three trials without receiving feedback, (b) between six and ten trials with feedback of electromyographic activity, (c) three trials without feedback. In each trial, isometric contractions of the vastus lateralis were performed.~During maximum effort isometric contraction, the software associated with the ProComp Infiniti biofeedback unit collects the amplitude, the mean and maximum electromyographic signal, and also the contraction and tightening times. The contrac-tion time comprises the interval between the start of the contraction and achievement of the desired muscle tension. The tightening time is the period in which the tension voluntarily reached is maintained. For this study, the maximum and mean elec-tromyographic activity values were considered, calculated during the muscle tension time and maintained during each trial.
Study: NCT01378715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
Study: NCT02411617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drain
Description: Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drain
Description: Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
Study: NCT02185898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leading U.S. non-menthol cigarette
Description: Tobacco-burning non-menthol cigarette

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leading U.S. menthol cigarette
Description: Tobacco-burning menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette #1
Description: Electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette #2
Description: Electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette #3
Description: Electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: U.S. Market-sample electronic cigarettes
Description: Marketed electronic cigarettes
Study: NCT04231162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active product
Description: Bifidobacterium lactis HN019 (probiotic powder). One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Placebo. One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
Study: NCT00969969

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis
Description: arthrodesis using screws and/or a plate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartiva
Description: Cartiva Synthetic Cartilage Implant